Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Toxicities Associated With IDH Inhibitors

August 12th 2021

A panel of key opinion leaders in acute myeloid leukemia reflects on the importance of considering the toxicity profiles of IDH inhibitors and emphasizes the challenges of diagnosing differentiation syndrome.

High-Risk MDS: Prognostic and Predictive Factors

August 12th 2021

Mikkael A. Sekeres, MD, explores prognostic and predictive factors inherent to high-risk MDS, including age and molecular abnormalities.

MDS: Risk Assessment Tools

August 12th 2021

Yazan Madanat, MD, discusses available MDS risk assessment tools and provides insight into his preferred clinical assessment methods.

Loncastuximab Tesirine and Ibrutinib Combination Shows Promise in R/R DLBCL and MCL

August 11th 2021

The combination of loncastuximab tesirine-lpyl and ibrutinib displayed encouraging antitumor activity with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma and mantle cell lymphoma.

Optimal Frontline Hodgkin Lymphoma Treatment Requires Careful Consideration of Toxicities

August 11th 2021

Alison J. Moskowitz, MD, discusses recent developments made in the Hodgkin lymphoma paradigm, shared advice for optimal stratification, and spotlighted potential emerging prognostic markers that might further help to guide treatment decisions.

MRD Testing in ALL

August 10th 2021

An overview of the treatment implications of testing for minimal residual disease in pediatric and AYA patients with ALL.

Choosing a Treatment Setting for Patients With ALL

August 10th 2021

Drs Aldoss and McCloskey share their thoughts on treating patients with ALL at community centers versus at tertiary, academic medical centers.

Key Clinical Data for Frontline Targeted Therapy in CLL

August 9th 2021

Shared insight on clinical trial data for frontline targeted agents—specifically ibrutinib, acalabrutinib, and venetoclax—in chronic lymphocytic leukemia.

Global Approaches to the Frontline Management of CLL

August 9th 2021

Considering a patient’s age, as well as their deletion 17p and IgHV status, experts from around the world share their approach to the frontline management of CLL.

Recommendations for CAR T-Cell Therapy in R/R DLBCL

August 9th 2021

Experts in lymphoma explain when and for which patients CAR T therapies are recommended in R/R DLBCL.

Case 1: 75-Year-Old Man With SM

August 9th 2021

Dan DeAngelo, MD, PhD, presents the case of a 75-year-old man with systemic mastocytosis and reviews WHO diagnostic criteria.

Newer Approvals for Previously Treated DLBCL

August 9th 2021

A panel of experts review the FDA approvals of loncastuximab tesirine and selinexor for the treatment of DLBCL in patients who have received at least 2 prior therapies.

Considerations in SM: Hereditary Alpha Tryptasemia

August 9th 2021

Prithviraj Bose, MD, and Patricia Lugar, MD, MS, discuss the considerations and testing options for hereditary alpha tryptasemia in patients with systemic mastocytosis.

FDA Places Partial Clinical Hold on Trials Examining Eprenetapopt/Azacitidine for Myeloid Malignancies

August 6th 2021

The FDA has placed a partial clinical hold on clinical trials examining the combination of eprenetapopt and azacitidine in patients with myeloid malignancies.

Treatment of Transfusion Dependent MDS

August 6th 2021

The panel of experts reflect on the use of lenalidomide in patients with myelodysplastic syndrome who are transfusion dependent.

Luspatercept: An Erythroid Maturation Agent in MDS

August 6th 2021

Rami Komrokji, MD discusses the recent approval and FDA indication for the use of the erythroid maturation agent luspatercept.

Clinical Considerations in the Diagnosis of MDS

August 5th 2021

Drs Madanat and Sekeres comment on the various risk stratification factors and prognostic criteria used in the classification of MDS disease.

The Role of IDH Inhibitors for Treatment of AML

August 5th 2021

Harry Erba, MD, PhD; Courtney DiNardo, MD; and Dan Pollyea, MD, MS, discuss the role of the IDH inhibitors ivosidenib and enasidenib as single-agent or combination therapy in patients with acute myeloid leukemia (AML).

Combining and Sequencing FLT3 Inhibitors in AML

August 5th 2021

Harry Erba, MD, PhD; Courtney DiNardo, MD; Mark Levis, MD, PhD; and Vinod Pullarkat, MD, review factors to consider when using combining and/or sequencing first- or second-generation FLT3 inhibitors for patients with acute myeloid leukemia (AML).

Classification of Myelodysplastic Syndrome

August 5th 2021

Yazan Madanat, M.D and Mikkael A. Sekeres, M.D. discuss considerations in the classification of myelodysplastic syndrome taking into account disease heterogeneity.